Xiamen Amoytop Biotech Co.Ltd(688278)
Performance report of the audit committee of the board of directors in 2021
In accordance with the relevant provisions of the standards for the governance of listed companies, the Listing Rules of the Shanghai Stock Exchange on the science and innovation board, the guidelines for the self-regulation of companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, the articles of association and other relevant provisions, Xiamen Amoytop Biotech Co.Ltd(688278) (hereinafter referred to as the “company”) all members of the audit committee of the board of directors have performed their duties diligently, and the performance report for 2021 is as follows:
1、 Basic information of the audit committee
On September 10, 2021, the first meeting of the eighth board of directors elected Mr. Liu Qi (independent director), Mr. Li Jiahong (director) and Ms. Jiang Xiaohui (independent director) as members of the audit committee of the eighth board of directors, with Mr. Liu Qi, an independent director with professional accounting qualification as the convener, and Ms. Jia Lina, a member of the audit committee of the seventh board of directors Mr. Li Chaodong and Mr. Wang Junye left office due to the expiration of their terms of office during the reporting period. 2、 Meetings held
In 2021, the audit committee of the board of directors of the company held four meetings, as follows:
On March 30, 2021, The first meeting of the audit committee of the seventh board of directors in 2021 deliberated and approved the proposal on the company’s 2020 annual financial statement report, the proposal on the company’s 2020 annual report and its summary, the proposal on the company’s 2020 profit distribution plan, the proposal on the renewal of the appointment of the accounting firm, and the proposal on the company’s 2020 internal control evaluation report Proposal on the special report on the deposit and actual use of the company’s raised funds in 2020, proposal on the performance report of the audit committee of the board of directors in 2020 and proposal on the change of accounting policies.
On April 26, 2021, the second meeting of the audit committee of the seventh board of directors in 2021 deliberated and adopted the proposal on the company’s report for the first quarter of 2021.
On August 24, 2021, the third meeting of the audit committee of the seventh board of directors in 2021 deliberated and approved the proposal on the company’s 2021 semi annual report and its summary, the proposal on the special report on the deposit and actual use of the company’s 2021 semi annual raised funds, and the proposal on the use of some idle raised funds for cash management.
On October 27, 2021, the first meeting of the audit committee of the eighth board of directors deliberated and adopted the proposal on the third quarter report of the company in 2021.
3、 Main work and performance of the audit committee
(I) supervise and evaluate the work of external audit institutions
In 2021, the audit committee supervised the annual audit work of the audit institution Rongcheng Certified Public Accountants (special general partnership) (hereinafter referred to as “Rongcheng certified public accountants”), and discussed and communicated with accountants on audit scope, audit plan, audit method and other matters. The Audit Committee believes that Rongcheng certified public accountants has many years of audit service experience in listed companies. During the audit of the company, Rongcheng certified public accountants was diligent and conscientious, followed the professional standards of independence, objectivity and impartiality, and completed all the audit work of the company as planned.
(II) guidance and evaluation of the company’s internal audit
In 2021, according to the requirements of the company law and other relevant laws and regulations, the audit committee carefully listened to the work report of the company’s internal audit department and put forward guiding opinions on the internal audit work. During the reporting period, the company’s internal audit department focused on the supervision of financial management, contract performance, related party transactions, fund occupation, use of raised funds and other matters, and continued to promote the optimization of the company’s internal control system.
(III) review of the company’s financial report
In 2021, the audit committee carefully reviewed the company’s financial reports for each period and considered that the company’s financial reports were true, accurate and complete, without fraud, fraud and other major misstatement. The content and format of the financial reports complied with the provisions of the CSRC and Shanghai Stock Exchange, and fairly reflected the company’s financial status and operating results.
(IV) guidance and review of the company’s internal control
In 2021, the audit committee listened carefully to the reports of the management and the internal audit department, continued to pay attention to the implementation of the company’s internal control system, urged the company to continuously improve the internal control system, and provided professional suggestions on improving the company’s internal control system from a professional perspective, so as to promote the healthy and stable development of the company.
(V) review related party transactions of the company
In 2021, based on the principles of independence, objectivity, impartiality and professionalism, the audit committee paid special attention to the company’s related party transactions by consulting the relevant materials of the company’s related parties and fully communicating with the management. After verification, the company did not have related party transactions during the reporting period, and there was no damage to the interests of the company and shareholders. 4、 Overall evaluation
In 2021, the audit committee adhered to the professional standards of independence, objectivity and impartiality, scrupulously performed its duties and duties, gave full play to their professional advantages, prompted the company to continuously optimize its internal control system, better performed the duties of the audit committee, and effectively protected the legitimate rights and interests of the company and shareholders.
In 2022, the audit committee will continue to play the role of supervision and review, perform its duties in improving and improving the company’s internal control system, improving the quality of internal audit, strengthening risk management awareness, coordinating external audit work and the implementation of major events of the company, and safeguard the interests of the company and all shareholders.
Xiamen Amoytop Biotech Co.Ltd(688278) board of directors audit committee
March 30, 2022
